{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:21:40Z","timestamp":1774624900900,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Taishan Scholars Program","award":["tspd20210321"],"award-info":[{"award-number":["tspd20210321"]}]},{"name":"Taishan Scholars Program","award":["tsqn202408342"],"award-info":[{"award-number":["tsqn202408342"]}]},{"name":"Taishan Scholars Program","award":["tstp20230653"],"award-info":[{"award-number":["tstp20230653"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470153"],"award-info":[{"award-number":["82470153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270174"],"award-info":[{"award-number":["82270174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370165"],"award-info":[{"award-number":["82370165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300189"],"award-info":[{"award-number":["82300189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH209"],"award-info":[{"award-number":["ZR2024MH209"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH073"],"award-info":[{"award-number":["ZR2023QH073"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with acute myeloid leukemia (AML) are still at risk of relapse after consolidation therapy with cytarabine. Therefore, early identification and intervention of patients at high risk of relapse is crucial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study analyzed the clinical data of 355 patients with AML (non-APL) who received cytarabine consolidation therapy. Key factors affecting relapse were identified by least absolute shrinkage and selection operator regression, and a predictive model for relapse after cytarabine consolidation therapy was constructed and internally validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study showed that age \u226550\u2009years, female, DNMT3A mutation, TP53 mutation, IDH1 mutation, CBF-AML, white blood cell (WBC) \u226530\u2009\u00d7\u2009109\/L, 2 courses of induction therapy, 1-2 courses of cytarabine consolidation therapy and cumulative dose of cytarabine &amp;lt;36\u2009g were significantly correlated with relapse after cytarabine consolidation therapy in AML patients. Constructing a nomogram using the above factors and validating it with receiver operating characteristic, calibration curves showed that it has good discrimination and prediction. Patients were categorized into high-risk and low-risk groups based on the median risk score of the model, and there were significant differences in overall survival and event-free survival between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Predictive models based on age, sex, DNMT3A, TP53, IDH1, CBF-AML, WBC count, induction therapy course, cytarabine consolidation course, and cumulative dose can effectively assess the relapse risk after receiving cytarabine consolidation therapy in AML patients and provide a reference for clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag088","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:48:39Z","timestamp":1773330519000},"source":"Crossref","is-referenced-by-count":0,"title":["Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients"],"prefix":"10.1093","volume":"31","author":[{"given":"Min","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]},{"name":"Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]},{"name":"Interdisciplinary Center, Shandong University , Jinan 250100,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruinan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u011bi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumin","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]},{"name":"Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-8235","authenticated-orcid":false,"given":"Jingjing","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]},{"name":"Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital, Shandong University , Jinan 250012,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026032710125310600_oyag088-B1","first-page":"17","article-title":"Acute myeloid leukemia, version 2.2021 featured updates to the NCCN guidelines","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compreh Can Net"},{"key":"2026032710125310600_oyag088-B2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/PO.20.00387","article-title":"Inherited susceptibility to hematopoietic malignancies in the era of precision oncology","volume":"5","author":"Roloff","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026032710125310600_oyag088-B3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/0284186X.2021.1955969","article-title":"Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis","volume":"60","author":"Pasvolsky","year":"2021","journal-title":"Acta Oncol"},{"key":"2026032710125310600_oyag088-B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark Res"},{"key":"2026032710125310600_oyag088-B5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/OP.24.00027","article-title":"Outcomes of patients with newly diagnosed AML and hyperleukocytosis","volume":"20","author":"Haddad","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026032710125310600_oyag088-B6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/ajh.27187","article-title":"Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: a study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party","volume":"99","author":"Moukalled","year":"2024","journal-title":"Am J Hematol"},{"key":"2026032710125310600_oyag088-B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.stem.2018.07.005","article-title":"AML: predicting the unpredictable","volume":"23","author":"Takahashi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2026032710125310600_oyag088-B8","doi-asserted-by":"crossref","first-page":"e31249","DOI":"10.1016\/j.heliyon.2024.e31249","article-title":"Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"2026032710125310600_oyag088-B9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026032710125310600_oyag088-B10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"2026032710125310600_oyag088-B11","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026032710125310600_oyag088-B12","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: users\u2019 guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"JAMA"},{"key":"2026032710125310600_oyag088-B13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1472-6947-8-53","article-title":"Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers","volume":"8","author":"Vickers","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026032710125310600_oyag088-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026032710125310600_oyag088-B15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"2026032710125310600_oyag088-B16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MOH.0000000000000124","article-title":"Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia","volume":"22","author":"Ustun","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"2026032710125310600_oyag088-B17","first-page":"608","article-title":"Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy","volume":"110","author":"Mosna","year":"2025","journal-title":"Haematologica"},{"key":"2026032710125310600_oyag088-B18","first-page":"2024","article-title":"Survival of adult AML patients treated with chemotherapy in the US population by age, race and ethnicity, sex, calendar-year period, and AML subgroup","volume":"71","author":"Linet","year":"2004","journal-title":"Eclinicalmedicine"},{"key":"2026032710125310600_oyag088-B19","doi-asserted-by":"crossref","first-page":"107586","DOI":"10.1016\/j.leukres.2024.107586","article-title":"Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: a single centre retrospective experience","volume":"147","author":"Chen","year":"2024","journal-title":"Leuk Res"},{"key":"2026032710125310600_oyag088-B20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1055-9965.EPI-20-0036","article-title":"Sex differences in cancer incidence and survival: a pan-cancer analysis","volume":"29","author":"Dong","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026032710125310600_oyag088-B21","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv"},{"key":"2026032710125310600_oyag088-B22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"key":"2026032710125310600_oyag088-B23","doi-asserted-by":"crossref","first-page":"12761","DOI":"10.1038\/s41598-020-69691-8","article-title":"Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients","volume":"10","author":"Lauber","year":"2020","journal-title":"Sci Rep"},{"key":"2026032710125310600_oyag088-B24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40246-025-00792-z","article-title":"Comparative outcome and prognostic factor analysis among MDS\/AML patients with TP53 mutations, snps, and wild type","volume":"19","author":"Yang","year":"2025","journal-title":"Hum Genomics"},{"key":"2026032710125310600_oyag088-B25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5045\/br.2021.2021152","article-title":"IDH1\/2 mutations in acute myeloid leukemia","volume":"57","author":"Byun","year":"2022","journal-title":"Blood Res"},{"key":"2026032710125310600_oyag088-B26","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-16-2628","article-title":"Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"23","author":"Xu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026032710125310600_oyag088-B27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-025-01751-w","article-title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort","volume":"18","author":"Cortes","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026032710125310600_oyag088-B28","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study","volume":"34","author":"Stahl","year":"2020","journal-title":"Leukemia"},{"key":"2026032710125310600_oyag088-B29","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1080\/10428190701632848","article-title":"Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)\/t(3; 3) (q21; q26) positive AML [J]","volume":"48","author":"Weisser","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2026032710125310600_oyag088-B30","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.35308","article-title":"Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10\/10 or 9\/10 unrelated donor: an acute leukemia working party European Society for Blood and Marrow Transplantation Study","volume":"130","author":"Loke","year":"2024","journal-title":"Cancer"},{"key":"2026032710125310600_oyag088-B31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16; 16)(p13; q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026032710125310600_oyag088-B32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s44178-024-00088-7","article-title":"Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients","volume":"3","author":"Hao","year":"2024","journal-title":"Holist Integ Oncol"},{"key":"2026032710125310600_oyag088-B33","doi-asserted-by":"crossref","first-page":"e35806","DOI":"10.1002\/cncr.35806","article-title":"Therapeutic horizon of acute myeloid leukemia: success, optimism, and challenges","volume":"131","author":"Senapati","year":"2025","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag088\/67370320\/oyag088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag088\/67370320\/oyag088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag088\/67370320\/oyag088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:13:03Z","timestamp":1774620783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag088\/8524926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag088","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"oyag088"}}